Hideyuki Kurata joined Asahi Glass Company in 1987, and currently serves as the General Manager of the newly formed AGC LifeScience General Division, responsible for growth and business development. Mr. Kurata brings 30 years of experience in the chemical and contract manufacturing industries and has held several key executive positions, where he was entrusted with the responsibilities of designing and launching several chemical plants, as well as developing new business and planning AGC’s semiconductor vertical. In addition to that, Mr. Kurata held the position of President and Chief Executive Officer of AGC Chemicals Americas for five years, where he successfully executed the turnaround of the struggling organization.
Mr. Kurata is a graduate of Waseda University in Japan, and holds a Bachelor of Science and Masters Degree, both in the field of Chemical Engineering.
Gustavo Mahler, Ph.D., joined AGC Biologics (previously CMC Biologics) in 2008 as President. In 2010, he was named global Chief Operations Officer and in January, 2016 he became Chief Executive Officer. Prior to joining CMC Biologics, Gustavo worked for 15 years at Bayer in the United States, Europe, and Latin America, serving in various manufacturing and general management positions.
Gustavo received his Ph.D. in Biochemistry from the University of Buenos Aires, and holds a Master of Business Administration from the University UNED of Madrid and an Executive Certification in Management from MIT Sloan.
Masahiko Fukamachi joined Asahi Glass Co. (AGC) in 1985, and has been working for AGC’s business segments (Building Glass, Automotive Glass, Display Glass, Chlor & Alkali chemical) as a business administrator covering Finance & Control, HR, IT, Purchase, and Compliance. From 1997 to 2001, Masahiko served as Executive Director in the Chemical business subsidiary in Thailand; from 2004 to 2007, he held the role of Executive Director in the Display Glass Business Subsidiaries in Indonesia, and from 2010 to 2016, he served as General Manager in Building & Automotive Glass at the Japan-Asia HQ Business Administration Office.
Patricio Massera joined AGC Biolgics (previously CMC Biologics) in August 2012 as General Manager and Managing Director of the CMC Biologics A/S based in Copenhagen. He has been working in Biologics for the last 20 years. Along his career, Patricio has held several key executive positions at MSD AH, Intervet/Schering-Plough, Biogenesis-Bagó, and other Biotech companies in Spain, Brazil, and Argentina developing, manufacturing and controlling biotechnological products and vaccines for human health and animal health. He led a staff of more than 250 employees operating large scale manufacturing facilities. He has acted as change agent in several integration processes and developed strong leadership teams.
Patricio holds Biochemist degree from University of Buenos Aires and a Master of Business Administration from UCEMA.
Robert (Bob) Broeze joined AGC Biolgics (previously CMC Biologics) in 2015 and serves as Chief Business Officer, responsible for global sales and marketing. He brings more than 30 years of experience in the biopharmaceutical and contract manufacturing industries, including holding positions of Senior VP, Business Development at Gallus Biopharmaceuticals, LLC (now Patheon Biologics) and Chief Commercial Officer and Chief Executive Officer at Laureate BioPharma. His technical expertise spans research, development, protein characterization, validation, testing, and cGMP manufacture of biopharmaceutical products, from pilot to Phase III clinical and commercial scale, with a strong emphasis on monoclonal antibody products for therapeutic and diagnostic use. Bob has also held senior positions in R&D and operations at Purdue BioPharma L.P., Bard BioPharma L.P and at Cytogen Corporation.
Bob is a graduate of Rensselaer Polytechnic Institute where he earned his BS and Ph.D. degrees.
Ikuo Matsukura joined Asahi Glass Co. (AGC) in 1986 as a Chemical process engineer in the Chemical Divisional R&D Center. He has over 30 years of experience in development of Fluorine containing polymer products. During the period of 2005 through 2009, he also worked as a corporate investor in Silicon Valley, CA, where he sought business opportunities for AGC.
Ikuo has a Master Degree in Chemistry from Yamaguchi University JP, and has held the Professional Engineer in Chemistry of Japan as a National Qualification since 2014.
SoYoung Kwon joined AGC Biologics (previously CMC Biologics) in 2015 as Vice President of Legal Affairs. She brings more than 20 years of experience as a corporate attorney and business executive with responsibility for all legal matters, including complex product licensing, research and development, commercial disputes/litigation management, board governance, corporate compliance, HR/Employment, general corporate, and transactional matters. Ms. Kwon has served as primary counsel to the board and all board committees, and has partnered with management and business leaders to achieve business initiatives.
SoYoung holds a Juris Doctorate from Willamette University College of Law and a Master of Law in Asian and Comparative Law from the University of Washington School of Law.
Paul joined AGC Biologics (previously CMC Biologics) in 2015 as Vice President for the Quality Department. He brings more than 25 years of experience in development of protein and small molecule products. Prior to CMC Biologics, he held positions of increasing responsibilities at Amgen and Eli Lilly in operations, quality, and analytical development.
Paul has a Ph.D. in Chemistry from Texas A&M University and a Bachelor of Science in Applied Chemistry from Harvey Mudd College.
Daisy joined AGC Biologics (previously CMC Biologics) in April 2017 as the Global Vice President of Human Resources. She brings over 18 years of professional Human Resources and Operations Management experience from various industries including Financial Services, High Tech, and Power Generation, working with organization sizes ranging from start-ups to global Fortune 100.
A native of Canada, Daisy holds an MBA from Azusa Pacific University in S. CA, and a Bachelor of Commerce degree in Human Resources Management and Entrepreneurship from McGill University in Montreal.
Kasper Møller joined AGC Biologics (previously CMC Biologics) in 2006 as a Scientist, and has held the positions of Principal Scientist (2007) and Department Manager (2008) within development. Beginning in 2010, Kasper lead the Upstream Process Development teams, and in 2011, lead process characterization and validation activities. In 2013, Kasper was appointed Vice President of Manufacturing. Prior to CMC Biologics, he spent five years as an assistant professor and faculty member at the Technical University of Denmark, conducting research and teaching within fermentation technology and metabolic engineering studies.
Kasper has a Ph.D. in Biochemical Engineering from the Technical University of Denmark, and pursued post-doctoral studies at Washington University Medical School in St Louis, Missouri.
Vy Nguyen joined AGC Biologics (previously CMC Biologics) in November 2014 as General Manager. He manages the startup and day-to-day site operations of CMC Biologics’ Berkeley manufacturing facility. Vy brings more than 25 years of biopharmaceutical industry expertise in the areas of clinical and commercial biologics manufacturing, strategic planning, and operations management from Bayer HealthCare.
Vy received his Bachelor of Science in Business Administration from Dominican University of California.